INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 426m ago
HOUSE PTR25m ago
SEC 13F25m ago
ROBINHOOD CHAIN25m ago
SEC FORM 4/Grant or awardVerified dataRule 10b5-1 plan

Burroughs Amy L. reported TERN

Director, Chief Executive Officer · Terns Pharmaceuticals, Inc. · Terns Pharmaceuticals, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
300.0K
Price
—
Executed
Jan 14, 2026
Disclosed
Jan 16, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 14 executedJan 16, 2026 disclosed

TERN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TERN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    KE
    Kuriakose EmilChief Medical Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award
    		A—
    56.3K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    14.6K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    11
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$282K
    7,521 sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KE
    Kuriakose EmilChief Medical Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award
    		A—
    112.5K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    11
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award · 10b5-1 plan
    		A—
    150.0K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    6
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$126K
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    6
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$126K
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    2
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$68K
    14.6K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    18
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.27M
    61.2K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    QM
    Quigley Jill M.Director
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    24.5K sh
    		Nov 4, 2025Nov 5, 2025
    traded Nov 4, 2025
    		+1dSEC FORM 4

    Evidence

    2
    QM
    Quigley Jill M.Director
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$227K
    24.5K sh
    		Nov 4, 2025Nov 5, 2025
    traded Nov 4, 2025
    		+1dSEC FORM 4

    Evidence

    23
    QM
    Quigley Jill M.Director
    TERNTerns Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$441K
    24.5K sh
    		Nov 4, 2025Nov 5, 2025
    traded Nov 4, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001872564-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 14, 2026
    Published
    Jan 16, 2026
    Ingested by INSIDER
    Nov 5, 04:22 UTC
    Last re-read
    Nov 5, 04:22 UTC

    Extracted facts

    Filer
    Burroughs Amy L.
    Role
    Director, Chief Executive Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Terns Pharmaceuticals, Inc. — Stock Option (Right to Buy)
    Ticker
    TERN
    Shares
    300.0K
    Price per share
    $0
    Execution date (reported)
    Jan 14, 2026
    Owned after transaction
    300.0K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Burroughs Amy L. filed this Form 4 reporting a grant or award of TERN on Jan 14, 2026. It became public on Jan 16, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Burroughs Amy L.cik:0001872564
    Issuer
    Terns Pharmaceuticals, Inc.cik:0001831363

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for TERN is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.